• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Stormy Daniels’ lawyer: No­var­tis made $400K in 'sus­pi­cious' pay­ments to Trump at­tor­ney Michael Co­hen

8 years ago
Pharma

Can you cut $600M in R&D costs with­out slash-and-burn tac­tics? Andy Plump aims to show us how

8 years ago
People
R&D

Dai­ichi scores in PhI­II study of AML drug, beat­ing chemo and build­ing its case for world­wide ap­provals

8 years ago
R&D

Atara en­lists Juno co-founder Michel Sade­lain in CAR-T ef­fort; Valeant no more, Bausch is the new mar­quee name

8 years ago
News Briefing

List­ing in Shang­hai, WuXi AppTec rais­es a $354M IPO for Chi­na R&D fa­cil­i­ties

8 years ago
Financing
Outsourcing

Io­n­is, Akcea team face some tough ques­tions on safe­ty as FDA in­sid­ers pon­der risks linked to volane­sors­en

8 years ago
Pharma

Poised to launch its first mar­ket­ing ef­fort, Al­ny­lam makes a big leap in­to CNS dis­eases and Alzheimer's

8 years ago
R&D

The (new) top 10 phar­ma com­pa­nies by 2017 rev­enue

8 years ago
Pharma

Take­da CEO Christophe We­ber fi­nal­ly clos­es on his $62B deal to buy Shire — now he has to con­vince share­hold­ers and ...

8 years ago
Deals

Au­to­lus en­gi­neers a $100M-plus IPO for it­self as it blue­prints a new gen­er­a­tion of bet­ter, safer cell ther­a­pies

8 years ago
Financing

Set to be the first pre-rev­enue biotech to list in Hong Kong, As­cle­tis lays out pri­or­i­ties in IPO ap­pli­ca­tion

8 years ago
Financing
China

Take­da clos­es in on a fi­nal $64B deal to buy Shire, starts to con­sid­er di­vesti­tures — re­ports

8 years ago
Deals

Al­ler­gan aes­thet­ics chief David Moataze­di be­comes CEO of Evo­lus; CARB-X in­vests $6.2M in­to Melin­ta's next-gen ...

8 years ago
News Briefing

Genen­tech R&D leader Di­et­mar Berg­er moves to Atara Bio, head­ing up off-the-shelf T cell work

8 years ago
People

Is bio­phar­ma’s first $1.5M ther­a­py now in Phase III?

8 years ago
Pharma
Cell/Gene Tx

As a promi­nent an­a­lyst pre­dicts (even­tu­al) drug price con­trols, bio­phar­ma braces for a blow while Trump balls his ...

8 years ago
Bioregnum
Opinion

FDA promis­es Roche a snap de­ci­sion on Tecen­triq triple for front­line lung can­cer as it falls even fur­ther be­hind ...

8 years ago
Pharma

With hits and miss­es in first piv­otal tri­als, J&J con­fi­dent­ly maps a path to the FDA with its ma­jor de­pres­sion med ...

8 years ago
R&D

Splat: Sin­ga­pore's Aslan tanks on Nas­daq de­but, rais­ing $42M in IPO and trend­ing down

8 years ago
Financing

Re­gen­eron ditch­es high­er dose of pain drug fas­inum­ab in PhI­II, trig­ger­ing safe­ty scare; In a small win for Al­ny­lam, ...

8 years ago
News Briefing

C4 Ther­a­peu­tics bumps An­drew Phillips to CEO; Milind Desh­pande ex­its Achillion; Leena Gand­hi to head up I/O at Eli ...

8 years ago
Peer Review

Cel­gene works to calm down anx­ious in­vestors, promis­ing to re-file ozan­i­mod at the FDA in ear­ly 2019

8 years ago
R&D

For shame: ‘Phar­ma Bro’ Shkre­li is in prison, but Dara­prim’s price is still high

8 years ago
Pharma

Sarep­ta CEO Doug In­gram scored a chart-top­ping $57M com­pen­sa­tion deal in 2017. Earn­ing it won’t be easy

8 years ago
People
First page Previous page 1029103010311032103310341035 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.